Xie, Shitong; Sheng, Yanan; Chuang, Ling-Hsiang; Wu, Jing - In: Health economics review 14 (2024) 1, pp. 1-10
Background Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with poor prognosis and heavy disease burden to patients. This study evaluated the cost-effectiveness of brentuximab vedotin (BV) in comparison to conventional chemotherapy in patients with RRcHL, from a Chinese...